Mereo BioPharma (MREO) Other Accumulated Expenses (2022 - 2026)

Mereo BioPharma (MREO) has reported Other Accumulated Expenses for 5 consecutive years, with $905000.0 the latest figure, recorded in Q1 2026.

• Quarterly Other Accumulated Expenses rose 1.23% year-over-year to $905000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $905000.0 (up 1.23% YoY) and the FY2025 annual result came in at $741000.0, down 32.33% from the prior year.
• Other Accumulated Expenses rose to $905000.0 in Q1 2026 per MREO's latest filing, from $741000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for MREO reached as high as $3.4 million in Q2 2024 and fell as low as $622000.0 in Q3 2025.
• A 5-year average of $1.3 million and a median of $905000.0 in 2026 frame the typical range for Other Accumulated Expenses.
• The largest YoY upside for Other Accumulated Expenses was 24.51% in 2025 against a maximum downside of 77.38% in 2025.
• Year by year, Other Accumulated Expenses stood at $1.1 million in 2022, then declined by 4.67% to $1.0 million in 2023, then grew by 7.25% to $1.1 million in 2024, then sank by 32.33% to $741000.0 in 2025, then rose by 22.13% to $905000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $905000.0, $741000.0, and $622000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.